Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6385372 | 0.79 | CYP1A2 (0.44) | FAAHNPC1RAB9AKDM4ERXFP1 | |
| SCHEMBL21206421 | 0.78 | KMT2A (0.38) | FAAHKMT2ACHRNA7 | |
| SCHEMBL6384282 | 0.78 | FAAH (0.40) | FAAHNPC1RAB9AKDM4ERXFP1 | |
| SCHEMBL6381453 | 0.78 | ALDH1A1 (0.42) | FAAHNPC1RAB9AKDM4ERXFP1 | |
| SCHEMBL6380218 | 0.77 | NPC1 (0.40) | FAAHNPC1RAB9AKDM4ERXFP1 | |
| SCHEMBL12797113 | 0.76 | GABRP (0.47) | FAAHKDM4ECYP1A2KMT2ACA9 | |
| SCHEMBL12797201 | 0.76 | CYP11B2 (0.41) | FAAHNPC1RAB9AKDM4ERXFP1 | |
| SCHEMBL2520510 | 0.75 | CDC7 (0.46) | CYP1A2KMT2AJMJD6 | |
| SCHEMBL2929174 | 0.74 | NPC1 (0.41) | NPC1RAB9AKDM4ERXFP1CYP1A2 | |
| SCHEMBL20926086 | 0.74 | KMT2A (0.35) | FAAHKMT2ACHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654868-B2 | Dihydropyrazole azepine compound serving as Akt inhibitor | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-10654868-B2 | Dihydropyrazole azepine compound serving as Akt inhibitor | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-20190233434-A1 | DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2019-08-01 | — | — | US | disclosed |
| US-20190233434-A1 | DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2019-08-01 | — | — | US | disclosed |
| EP-3473628-A1 | DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR | Medshine Discovery Inc. (CN) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017215588-A1 | DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR | 南京明德新药研发股份有限公司 | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654868-B2 | Dihydropyrazole azepine compound serving as Akt inhibitor | AKT3, AKT2, AKT1 | FAAH 4526/4885NPC1 554/4885RAB9A 290/4885 |
| US-20190233434-A1 | DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR | AKT3, AKT2, AKT1 | FAAH 4526/4885NPC1 554/4885RAB9A 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.